



**SECTION 1: IDENTIFICATION**

**1.1 Product identifier**

<b>Product name:</b>	Frusedale® (40mg oral tablets)
<b>Synonyms:</b>	Not Available
<b>Proper Shipping name:</b>	Not Available
<b>Other means of identification:</b>	None

**1.2 Relevant identified uses of the substances or mixture and uses advised against**

<b>Recommended uses:</b>	For the treatment of oedema associated with cardiac insufficiency, renal dysfunction and trauma in cats and dogs.  In animals with pulmonary oedema of cardiac origin, combined therapy with other medicinal products may be indicated.
<b>Uses advised against:</b>	Not for human use. Do not use in animals with acute glomerular nephritis, renal failure with anuria, electrolyte deficiency disease or in animals that have received an overdosage of digitalis. Do not use concurrently with aminoglycoside antibiotics. Do not use in animals weighing less than 4 kg.

**1.3 Details of the supplier of the substance or mixture**

<b>Registered company name:</b>	Dechra Ltd
<b>Address:</b>	Snaygill Industrial Estate Keighley Road Skipton North Yorkshire BD23 2RW UK
<b>Telephone:</b>	+44 (0) 1756 791311
<b>Fax:</b>	+44 (0) 1756 798604
<b>Email:</b>	Not available

**1.4 Emergency Telephone Numbers**

	+44 (0) 1756 791311
--	---------------------

**SECTION 2: HAZARDS IDENTIFICATION**

**2.1 Classification of the substance or mixture**

<b>DSD Classification (EU):</b>	Not Available
---------------------------------	---------------



<b>DPD Classification (EU)<sup>1</sup>:</b>	Not Available
<b>Classification according to regulation (EC) No 1272/2008 [CLP] (EU)<sup>1</sup>:</b>	Not Available
<b>2.2 Label Elements</b>	
<b>Signal Word:</b>	Not Available
<b>Hazard Statement(s)</b>	
Not Available	
<b>Additional Statement(s)</b>	
Not Available	
<b>Precautionary Statement(s) Prevention:</b>	
Not Available	
<b>Precautionary Statement(s) Response:</b>	
Not Available	
<b>Precautionary Statement(s) Storage:</b>	
Not Available	
<b>Precautionary Statement(s) Disposal:</b>	
Not Available	
<b>2.3 Other Hazard Information</b>	
Not Available	

### SECTION 3: INFORMATION ON THE INGREDIENTS

#### 3.1 Substances

See section below for composition of mixtures

#### 3.2 Mixtures

1.CAS No 2.EC Number 3.Index Number 4.REACH Number	% w/w	Name	Classification according to regulations (EC) No 1272/2008 [CLP] (EU)
1. 54-31-9 2. 200-203-6 3. Not Available 4. Not Available	40	Furosemide (Frusemide)	Reproductive Toxicity Category 1B; H360 <sup>1</sup>
<b>Legend:</b>	1. Classified by Chemwatch		



**SECTION 4: FIRST AID MEASURES**

**4.1 Description of first aid measures**

<b>Eye contact:</b>	In case of accidental contact of the product with the eyes rinse abundantly with copious amounts of fresh water. Seek medical attention, showing the package leaflet or the label to the medical practitioner.
<b>Skin contact:</b>	In case of accidental contact of the product with the skin rinse abundantly with fresh water. Seek medical attention if irritation persists, showing the package leaflet or the label to the medical practitioner. Gloves should be worn when handling the tablets.
<b>Inhalation:</b>	Remove to fresh air and seek medical attention.
<b>Ingestion:</b>	Following accidental ingestion, seek medical advice, showing the package leaflet to the medical practitioner. Treatment is symptomatic and includes replacement of fluid and electrolytes.

**4.2 Most important symptoms and effects, both acute and delayed**

See Section 11

**4.3 Indication of immediate medical attention and special treatment needed**

N/a

**SECTION 5: FIRE FIGHTING MEASURES**

**5.1 Extinguishing media**

<b>Suitable:</b>	All systems may be used.
<b>Unsuitable:</b>	None.

**5.2 Special hazards arising from the substance or mixture**

<b>Fire incompatibility:</b>	None known.
------------------------------	-------------

**5.3 Special protective actions for fire-fighters:**

<b>Firefighting:</b>	Alert Fire Brigade and tell them location and nature of hazard. Wear full breathing apparatus and self-contained breathing apparatus.
----------------------	---



<b>Fire / explosion hazard:</b>	<p>Avoid generating dust, particularly clouds of dust in a confined or unventilated space as dusts may form an explosive mixture with air, and any source of ignition, i.e. flame or spark, will cause fire or explosion. Dust clouds generated by the fine grinding of the solid are a particular hazard.</p> <ul style="list-style-type: none"> <li>• Combustion products include:</li> <li>• carbon monoxide (CO)</li> <li>• carbon dioxide (CO<sub>2</sub>)</li> <li>• hydrogen chloride</li> <li>• phosgene</li> <li>• nitrogen oxides (NO<sub>x</sub>)</li> <li>• sulfur oxides (SO<sub>x</sub>)</li> <li>• other pyrolysis products typical of burning organic material.</li> </ul> <p>Emits toxic fumes.</p>
---------------------------------	--

<b>SECTION 6: ACCIDENTAL RELEASE MEASURES</b>	
<b>6.1 Personal precautions, protective equipment and emergency procedures</b>	
For information on protective equipment, see section 8.	
<b>6.2 Environmental Precautions</b>	
Do not allow product to reach sewage system or any water course. Inform respective authorities in case of seepage into water course or sewage system. Do not allow to enter sewers/surface or ground water.	
<b>6.3 Methods and material for containment and cleaning up</b>	
<b>Minor Spills:</b>	Flush residues and small spillages to waste with copious quantities of water.
<b>Major Spills:</b>	Clean up all spills immediately. Large spills should be collected into an appropriate container for waste disposal. Control personal contact with the substance, by using protective equipment. Avoid contact with skin and eyes.



**SECTION 7: HANDLING AND STORAGE**

**7.1 Precautions for safe handling**

<b>Safe Handling:</b>	Wear suitable protection gloves and clothing when handling the product. Wash hands after use. Avoid contact and inhalation of dust/fumes associated with the product. When handling, <b>DO NOT</b> eat, drink or smoke. Observe manufacturer's storage and handling recommendations.
<b>Other Information:</b>	Keep out of the reach and sight of children.

**7.2 Conditions for safe storage, including any incompatibilities**

<b>Suitable Container:</b>	Do not store above 25°C. Protect from light. Shelf life of the veterinary medicinal product as packaged for sale: 4 years.
<b>Storage incompatibility:</b>	No major incompatibilities known.

**7.3 Specific end uses**

Not available

**SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION**

**8.1 Control parameters**

**DERIVED NO EFFECT LEVEL - DNEL**

Not Available

**PREDICTED NO EFFECT LEVEL - PNEC**

Not Available


**OCCUPATIONAL EXPOSURE LIMITS (OEL)**

**INGREDIENT DATA:**

Not Available

**EMERGENCY LIMITS:**

Ingredient	Material Name	TEEL-1	TEEL-2	TEEL-3
Not Available				

Ingredient	Original IDLH	Revised IDLH
Not Available		
<b>8.2 Exposure controls</b>		
<b>Appropriate engineering controls:</b>	The basic types of engineering controls are: Process controls which involve changing the way a job activity or process is done to reduce the particular risk.	
<b>Personal protection:</b>		
<b>Eye and face protection:</b>	Safety glasses with side shields / chemical goggles	
<b>Skin protection:</b>	See hand protection below	
<b>Hands/ feet protection:</b>	No special equipment needed when handling small quantities. OTHERWISE: Wear chemical protective gloves	
<b>Body protection:</b>	Wear appropriate clothing	
<b>Other protection:</b>	No special equipment needed when handling small quantities	
<b>Thermal hazards:</b>	Not applicable	
<b>Respiratory protection:</b>	Not applicable	
<b>8.3 Environmental exposure controls</b>		
See Section 12		



**SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**

**9.1 Information on basic physical and chemical properties**

**Appearance:** Frusedale®: White, circular, biconvex, flat-faced tablets with bevelled edges and a breakline.  
 Furosemide: A white or almost white, crystalline powder  
**Container:** Polypropylene containers containing 1000 white, circular, biconvex, flat-faced tablets with bevelled edges, a breakline and which are embossed F40 on one face, CP or DP on the reverse.  
**Physical state:** Solid  
**Odour:** Not available  
**Odour Threshold:** Not available  
**pH (as supplied):** Not available  
**Melting point / freezing point (degrees C):** Furosemide 210°C with decomposition  
**Initial boiling point and boiling range:** Not available  
**Flash Point:** Not available  
**Evaporation rate:** Not available  
**Flammability:** Not available  
**Upper/lower flammability or explosive limits:** Not available  
**Vapour pressure:** Not available  
**Relative Density (at degrees C):** Not available  
**Solubility in water and solvents (mg/l):** Furosemide practically insoluble  
**Vapour density:** Not available  
**Auto ignition temperature (degrees C):** Not available  
**Decomposition temperature (degrees C):** Not available  
**Viscosity: (degrees C):** Not available  
**Explosive properties:** Not available  
**Oxidising properties:** Not available  
**Partition Coefficient:** Not available  
**Molecular weight:** Furosemide 330.7  
**Taste:** Not available  
**Surface tension:** Not available  
**Volative component:** Not available  
**Gas group:** Not available  
**pH as a solution:** Not available  
**VOC g/L:** Not available

**9.2 Other information**  
 Not Available

**10: REACTIVITY AND STABILITY**

<b>10.1 Reactivity:</b>	See Section 7
<b>10.2 Chemical stability:</b>	Product is considered stable.
<b>10.3 Possibility of hazardous reactions:</b>	Stable under normal temperatures and conditions.
<b>10.4 Conditions to avoid:</b>	Avoid excessive heat.



	Exposure to light may cause discolouration.
<b>10.5 Incompatible materials:</b>	See section 7.
<b>10.6 Hazardous decomposition:</b>	See Section 5.

### SECTION 11: TOXICOLOGICAL INFORMATION

<b>Inhalation:</b>	Can be irritating to the respiratory tract.	
<b>Ingestion:</b>	Diuretic. Diuresis may result in dehydration, hypokalemia, hypocalcemia and orthostatic hypotension. Other symptoms include weakness, fatigue, nausea, vomiting, dryness of mouth, increased thirst, weak pulse, muscle cramp, pain, irregular heartbeat and mood/mental changes. Possible hypersensitisation.	
<b>Skin contact:</b>	Irritating to skin. Possible hypersensitisation.	
<b>Eye contact:</b>	Possible allergic reaction.	
<b>Chronic:</b>	Most adverse effects of furosemide occur with high doses, and serious effects are uncommon.  Administration at the recommended dosage level is not normally associated with undesirable effects.	
<b>Frusedale®:</b>	<b>Acute toxicity</b>	<b>Irritation</b>
	Not Available	Not Available
<b>Furosemide:</b>	<b>Acute toxicity</b>	<b>Irritation</b>
	Oral (rat) LD50: 2600 mg/kg <sup>1</sup> Mouse – 1050 mg/kg <sup>-1</sup> Rabbit – 720 mg/kg <sup>-1</sup> Dog – 1000 mg/kg <sup>-1</sup>	Not Available

1.\* Value obtained from manufacturer's SDS. Unless otherwise specified, data extracted from RTECS - Register of Toxic Effect of chemical Substances

**Skin corrosion/irritation:**

Can be irritating to the skin; there is a possibility for hypersensitisation.

**Serious eye damage/irritation:**

There is a risk of allergic reaction.

**Respiratory or skin sensitization:**

Not available

**Germ cell mutagenicity:**





**SECTION 11: TOXICOLOGICAL INFORMATION**

Not available
<b>Carcinogenicity:</b>
There has been some concern that Furosemide can cause cancer or mutations but there is not enough data to make an assessment.
<b>Reproductive toxicity:</b>
Not contraindicated in pregnant or lactating animals.
<b>STOT – single exposure:</b>
Not available
<b>STOT–repeated exposure:</b>
Not available
<b>Aspiration hazard:</b>
Not available

**SECTION 12: ECOLOGICAL INFORMATION**

Not expected to be an environmental hazard.		
<b>12.1 Toxicity</b>		
Not Available		
<b>12.2 Persistence and degradability</b>		
<b>Ingredient</b>	<b>Persistence: water/soil</b>	<b>Persistence: air</b>
Furosemide	HIGH	HIGH
<b>12.3 Bioaccumulative potential</b>		
<b>Ingredient</b>	<b>Bioaccumulation</b>	
Furosemide	LOW (LogKOW = 2.03)	
<b>12.4 Mobility in Soil</b>		
<b>Ingredient</b>	<b>Mobility</b>	
Furosemide	LOW (KOC = 188.3)	



<b>12.5 Results of PBT and vPvB assessment</b>
Not Available
<b>12.6 Other adverse effects</b>
Not Available

**SECTION 13: DISPOSAL CONSIDERATIONS**

<b>13.1 Waste treatment methods</b>	
<b>Product / packaging disposal:</b>	Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with national requirements.  Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area.  Ensure that the disposal of material is carried out in accordance with Hazardous Substances (Disposal) Regulations 2001.
<b>Waste Treatment Options:</b>	Not Available
<b>Sewage Disposal Options:</b>	Not Available

**SECTION 14: TRANSPORT INFORMATION**

<b>Labels required:</b>	None
<b>Marine pollutant:</b>	NO
<b>Hazchem:</b>	Not Applicable

<b>Land transport (ADR):</b>		
<b>14.1 UN Number</b>	N/a	
<b>14.2 UN Proper Shipping Name</b>	N/a	
<b>14.3 Transport hazard class(es)</b>	Class	N/a
	Sub risk	N/a
<b>14.4 Packing group</b>	N/a	
<b>14.5 Environmental hazards</b>	N/a	



<b>14.6 Special precautions for user</b>	Special provisions	N/a
	Classification code	N/a
	Hazard Label	N/a
	Special provisions	N/a
	Limited quantity	N/a
<b>14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code</b>	N/a	
<b>Air transport (ICAO-IATA / DGR):</b>		
<b>14.1 UN Number</b>	N/a	
<b>14.2 UN Proper Shipping Name</b>	N/a	
<b>14.3 Transport hazard class(es)</b>	ICAO/IATA Class	N/a
	ICAO / IATA Sub risk	N/a
	ERG Code	N/a
<b>14.4 Packing group</b>	N/a	
<b>14.5 Environmental hazards</b>	N/a	
<b>14.6 Special precautions for user</b>	Special provisions	N/a
	Cargo only packing instructions	N/a
	Cargo only maximum qty/pack	N/a
	Passenger and cargo packaging instructions	N/a
	Passenger and cargo maximum qty/pack	N/a
	Passenger and cargo limited quantity packing instructions	N/a
	Passenger and cargo limited maximum qty/pack	N/a



<b>14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code</b>	N/a	
<b>Sea transport (IMDG-Code / GGVSee):</b>		
<b>14.1 UN Number</b>	N/a	
<b>14.2 UN Proper Shipping Name</b>	N/a	
<b>14.3 Transport hazard class(es)</b>	IMDG Class	N/a
	IMDG Sub risk	N/a
<b>14.4 Packing group</b>	N/a	
<b>14.5 Environmental hazards</b>	N/a	
<b>14.6 Special precautions for user</b>	EMS Number	N/a
	Special provisions	N/a
	Limited quantities	N/a
<b>14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code</b>	N/a	
<b>Inland waterways transport (ADN):</b>		
<b>14.1 UN Number</b>	N/a	
<b>14.2 UN Proper Shipping Name</b>	N/a	
<b>14.3 Transport hazard class(es)</b>	N/a	N/a
<b>14.4 Packing group</b>	N/a	
<b>14.5 Environmental hazard</b>	N/a	
<b>14.6 Special precautions for user</b>	Classification Code	N/a
	Special provisions	N/a
	Limited quantity	N/a
	Equipment required	N/a
	Fire cones number	N/a
<b>14.7 Transport in</b>	N/a	



<b>bulk according to Annex II of MARPOL73/78 and the IBC Code</b>	
---	--

**SECTION 15: REGULATORY INFORMATION**

**15.1 Safety, health and environmental regulations / legislation specific for the substance or mixture**

**FUROSEMIDE (54-31-9) IS FOUND ON THE FOLLOWING REGULATORY LISTS:**

- European Customs Inventory of Chemical Substances ECICS (English)
- European Union - European Inventory of Existing Commercial Chemical Substances (EINECS) (English)
- International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

**15.2 Chemical Safety Assessment**

**ECHA SUMMARY**

Ingredient	CAS number	Index Number	ECHA Dossier
Furosemide	54-31-9	Not Available	Not Available

Harmonization (C&L Inventory)	Hazard Class and Category Code(s)	Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	Repr. 1B	GHS08, Dgr,	H360
2	Repr. 1B, Repr. 1A, Skin Irrit. 2, Eye Irrit. 2, STOT SE 3, Carc. 2, Repr. 2, Acute Tox. 3, Acute Tox. 4, Carc. 1B, Muta. 2, Lact., Aquatic Chronic 3, STOT RE 2	GHS08, Dgr, GHS06	H315, H319, H335, H301, H360Df, H350, H341, H373, H312, H332, H362, H412

Harmonization Code 1 = The most prevalent classification. Harmonization Code 2 = The most severe classification

Australia - AICS	Y
Canada - DSL	Y
Canada - NDSL	N (furosemide)
China - IECSC	N (furosemide)



Europe - EINEC / ELINCS / NLP	Y
Japan - ENCS	Y
Korea - KECI	Y
New Zealand - NZIoC	Y
Philippines - PICCS	Y
USA - TSCA	N (furosemide)
<b>Legend:</b>	<i>Y = All ingredients are on the inventory N = Not determined or one or more ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)</i>



## SECTION 16: OTHER INFORMATION

The SDS is written in accordance to guidelines specified by REACH, GHS and ECHA.

For detailed advice on Personal Protective Equipment, refer to the following EU CEN Standards:

- EN 166 Personal eye-protection
- EN 340 Protective clothing
- EN 374 Protective gloves against chemicals and micro-organisms
- EN 13832 Footwear protecting against chemicals
- EN 133 Respiratory protective devices

### Definitions and abbreviations

- PC—TWA: Permissible Concentration-Time Weighted Average
- PC—STEL: Permissible Concentration-Short Term Exposure Limit
- STEL: Short Term Exposure Limit
- TEEL: Temporary Emergency Exposure Limit
- IDLH: Immediately Dangerous to Life or Health Concentrations

The information provided in this Safety Data Sheet has been compiled by Dechra Ltd using a number of different sources, and is correct to the best of its knowledge, information and belief as at the date of its publication. However, Dechra Ltd makes no warranties, express or implied, in relation to the information set out in this Safety Data Sheet, including, without limitation, as to its accuracy or completeness.

The information provided is not a quality specification, and is prepared by way of guidance as to the safe handling, use, processing, storage, transportation, disposal and release of the relevant products referred to. The user is responsible for determining whether or not the product is fit for any particular purpose and/or suitable for the user's proposed method of use and application.

Copyright, 2017, Dechra Ltd. All rights reserved.

Copying and/or downloading of this information for the purpose of properly utilizing Dechra Ltd products is permitted provided that: (1) the information is copied in full with no changes unless prior written agreement is obtained from Dechra Ltd, and (2) neither the copy nor the original is resold or otherwise distributed for the purposes of making a profit thereon.